Google Ventures and others back universal flu vaccine firm Vaccitech

By Gareth Macdonald

- Last updated on GMT

Gettyimages/Ca-ssis
Gettyimages/Ca-ssis

Related tags Virus Vaccine Vaccination

Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.

The Oxford University spin-out announced the series A funding round this week explaining it will use the money to develop its portfolio of vaccines, which includes a universal influenza vaccine in Phase II development.

Vaccitech CEO Tom Evans told us, “We know the technology induces an immune response in humans based on the various first-in-man studies we have conducted​.”

He added the firm plans to use the venture capital funding to pay for all corporate activities, including product development.

Technology

The UK firm’s candidate vaccines consist of genes encoding pathogenic proteins loaded into adenovirus delivery vectors.

The adenoviruses Vaccitech uses - chimpanzee adenovirus Oxford 1 and 2 – are non-replicating.

The firm produces the viral vectors in the HEK293 cell line, which contains the adenoviral gene E1 that the viruses lack.  

Vaccination

Adenoviral vectors are an area of significant interest for both gene therapy and vaccine developers. 

Spark’s eye disease treatment Luxturna – which in December​ became the first gene therapy to be approved by the US Food and Drug Administration FDA) – is delivered using a modified adenovirus.

Developers have also employed adenoviruses in the delivery of vaccines. However, the immune responses such products generate mean multiple administration can be problematic​.

Vaccitech’s approach to this problem is to use its adenovirus vectors to deliver the initial dose of vaccine and then switch to a separate, unrelated vector called Modified vaccinia Ankara (MVA).

Evans told us, “The foreign gene is encoded into both the non-replicating adenovirus and the non-replicating MVA,​” adding “The adenovirus is given first, and then boosted with the MVA.​”

In addition to the influenza vaccine, which is in Phase IIb study, Vaccitech’s portfolio includes vaccines for the prevention of Middle East respiratory syndrome (MERS), human papillomavirus (HPV​) and hepatitis B (HBV​).

It also has several anti-cancer vaccines in development.

Related topics Bio Developments Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us

Products

View more

Webinars